Cantex News

Cantex Pharmaceuticals and Baptist Health Miami Cancer Institute, part of Baptist Health Cancer Care, the largest cancer program in South Florida, announced today that the U.S. Food and Drug Administration (FDA) has issued a “Study May Proceed” letter for the Miami Cancer Institute’s investigator initiated clinical trial to assess the...

WESTON, FL – September 14, 2021 – Cantex Pharmaceuticals, Inc. (“Cantex”) today announced that it has sold 6.5 million shares of Chimerix, Inc. in brokerage transactions at a price of $5.75 per share, less brokerage commissions and fees.   About Cantex Pharmaceuticals Cantex Pharmaceuticals, Inc. is a privately-held, clinical stage pharmaceutical company focused on the transformation...

  HIGH POINT, N.C. and WESTON, FL– June 22, 2021 – vTv Therapeutics Inc. ("vTv", Nasdaq:VTVT) and Cantex Pharmaceuticals, Inc. ("Cantex") today announced that they have entered into a licensing agreement under which Cantex has obtained exclusive worldwide rights to develop and commercialize azeliragon, vTv's novel antagonist of RAGE (the receptor...

Cantex Pharmaceuticals, Inc. today announced that Chimerix, Inc., to whom it licensed worldwide rights for the development and commercialization of its lead product, CX-01 (now known as DSTAT) has initiated a Phase 2/3 study of DSTAT in COVID-19 patients with acute lung injury (ALI)...